Immatics Fundamentals

IMTX -  USA Stock  

USD 13.00  0.42  3.13%

Immatics NV fundamentals help investors to digest information that contributes to Immatics' financial success or failures. It also enables traders to predict the movement of Immatics Stock. This fundamental analysis module provides a way for investors to measures Immatics' intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immatics stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Immatics Fundamentals 

 
Refresh

Immatics Shares Owned by Institutions Analysis

Immatics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
 2010 2019 2020 2021 (projected)
Current Assets55.29 M124 M238.99 M206.51 M
Total Assets61.32 M134.28 M254.65 M220.91 M
Shares Held by Institutions 
 = 
Funds and Banks 
Firms 
More About Shares Owned by Institutions | All Equity Analysis

Current Immatics Shares Owned by Institutions

    
  41.31 %  
Most of Immatics' fundamental indicators, such as Shares Owned by Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immatics NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Compare to competition

Based on the latest financial disclosure, 41.31% of Immatics NV are shares owned by institutions. This is 7.46% lower than that of the Healthcare sector and 13.03% lower than that of the Biotechnology industry. The shares owned by institutions for all United States stocks is 5.36% lower than that of the firm.

Immatics NV Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Immatics's current stock value. Our valuation model uses many indicators to compare Immatics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immatics competition to find correlations between indicators driving Immatics's intrinsic value. More Info.
Immatics NV is rated second overall in price to sales category among related companies. It is rated third overall in shares outstanding category among related companies creating about  2,431,774  of Shares Outstanding per Price to Sales.

Immatics Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immatics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immatics could also be used in its relative valuation, which is a method of valuing Immatics by comparing valuation metrics of similar companies.
Immatics is currently under evaluation in revenue category among related companies.

Immatics Institutional Holders

Institutional Holdings refers to the ownership stake in Immatics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immatics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immatics' value.
Security TypeSharesValue
Belvedere Trading LlcPut Options15.2 K204 K
Belvedere Trading LlcCommon SharesK40 K
Baker Bros Advisors LpCommon Shares4.3 M49.7 M
Nantahala Capital Management LlcCommon Shares2.5 M29.5 M
Perceptive Advisors LlcCommon Shares2.5 M29 M
Alyeska Investment Group LpCommon Shares2.2 M25 M
Redmile Group LlcCommon Shares1.9 M22.5 M
Federated Hermes IncCommon Shares1.8 M20.4 M
Beryl Capital Management LlcWarrantsM3.6 M

Immatics Fundamentals

About Immatics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immatics NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immatics NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2021
Deferred Revenue132.1 M138.7 M
Revenues31.3 M26.8 M
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed andor refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The companys TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications Amgen Inc. and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tbingen, Germany.

Immatics Investors Sentiment

The influence of Immatics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immatics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - IMTX

Immatics NV Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immatics NV. What is your judgment towards investing in Immatics NV? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immatics NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Immatics Piotroski F Score and Immatics Altman Z Score analysis. Note that the Immatics NV information on this page should be used as a complementary analysis to other Immatics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Immatics Stock analysis

When running Immatics NV price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics NV underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immatics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.